Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

This study tests a combination of immunotherapy (pembrolizumab) and radiation therapy for people with early-stage NK/T-cell lymphoma — a rare type of lymphoma often affecting the nose and sinuses — who are not well enough to receive full-dose chemotherapy. **You may be eligible if...** - You have a confirmed diagnosis of NK/T-cell lymphoma - You have never been treated for this lymphoma before - You are 18 or older - Your disease is at an early stage (stage I or II) and you have at least one high-risk feature (such as age over 60, elevated LDH, or stage II disease) - You are not well enough to receive full standard chemotherapy - You are in generally good health otherwise (ECOG 0–1) **You may NOT be eligible if...** - Your lymphoma has spread to advanced stages (stage III or IV) - You have an autoimmune disease - You have another active cancer that has not been cured - You have a history of severe lung inflammation Talk to your doctor to see if this trial is right for you.